Literature DB >> 24816306

Prostate cancer: measuring PSA.

C Pezaro1, H H Woo, I D Davis.   

Abstract

Population screening with prostate-specific antigen (PSA) for detection of prostate cancer is a topic associated with ongoing dissent and confusion within the oncology and wider medical community. The PSA blood test has been used in various stages of prostate cancer management, including screening and the assessment of future risk of prostate cancer development, detection of recurrent disease after local therapy and in the management of advanced disease. However, PSA-based decision-making in prostate cancer has significant shortcomings. This review will summarise the evidence and current recommendations for the use of PSA in detection and management of prostate cancer.
© 2014 The Authors; Internal Medicine Journal © 2014 Royal Australasian College of Physicians.

Entities:  

Keywords:  monitoring; prostate cancer; prostate-specific antigen (PSA); risk assessment; screening

Mesh：

Substances：

Year:  2014        PMID： 24816306     DOI： 10.1111/imj.12407

Source DB:  PubMed          Journal:  Intern Med J        ISSN： 1444-0903            Impact factor:   2.048


  27 in total

Review 1.  Ca2+ as a therapeutic target in cancer.

Authors:  Scott Gross; Pranava Mallu; Hinal Joshi; Bryant Schultz; Christina Go; Jonathan Soboloff
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

2.  Associations Between Genetically Predicted Plasma N-Glycans and Prostate Cancer Risk: Analysis of Over 140,000 European Descendants.

Authors:  Duo Liu; Jingjing Zhu; Tianying Zhao; Sodbo Sharapov; Evgeny Tiys; Lang Wu
Journal:  Pharmgenomics Pers Med       Date:  2021-09-22

3.  Step-adjusted tree-based reinforcement learning for evaluating nested dynamic treatment regimes using test-and-treat observational data.

Authors:  Ming Tang; Lu Wang; Michael A Gorin; Jeremy M G Taylor
Journal:  Stat Med       Date:  2021-09-07       Impact factor: 2.373

4.  MYB interacts with androgen receptor, sustains its ligand-independent activation and promotes castration resistance in prostate cancer.

Authors:  Sanjeev Kumar Srivastava; Mohammad Aslam Khan; Shashi Anand; Haseeb Zubair; Sachin Kumar Deshmukh; Girijesh Kumar Patel; Seema Singh; Joel Andrews; Bin Wang; James Elliot Carter; Ajay Pratap Singh
Journal:  Br J Cancer       Date:  2021-11-26       Impact factor: 9.075

5.  miR-138-5p inhibits the malignant progression of prostate cancer by targeting FOXC1.

Authors:  Dapeng Zhang; Xiaodong Liu; Qingwei Zhang; Xin Chen
Journal:  Cancer Cell Int       Date:  2020-07-09       Impact factor: 5.722

6.  Characterization of Kinase Expression Related to Increased Migration of PC-3M Cells Using Global Comparative Phosphoproteome Analysis.

Authors:  Yan Gao; Yun-Sok Ha; Tae Gyun Kwon; Young-Chang Cho; Sangkyu Lee; Jun Nyung Lee
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

7.  Comparison of the Efficacy of Two Brands of Triptorelin (Microrelin and Diphereline) in Reducing Prostate-Specific Antigen and Serum Testosterone in Prostate Cancer: A Double-Blinded Randomized Clinical Trial.

Authors:  Farid Fazeli; Mohammad Reza Nowroozi; Mohsen Ayati; Sahar Latifi; Mohsen Taheri Mahmoodi; Abbas Norouzi Javidan; Hassan Jamshidian; Amir Arbab
Journal:  Nephrourol Mon       Date:  2015-05-25

8.  Anti-Cancer Effect of Lambertianic Acid by Inhibiting the AR in LNCaP Cells.

Authors:  Myoung-Sun Lee; Seon-Ok Lee; Sung-Hoon Kim; Eun-Ok Lee; Hyo-Jeong Lee
Journal:  Int J Mol Sci       Date:  2016-07-07       Impact factor: 5.923

Review 9.  Neutrophil-to-Lymphocyte Ratio Predicts PSA Response and Prognosis in Prostate Cancer: A Systematic Review and Meta-Analysis.

Authors:  Jian Cao; Xuan Zhu; Xiaokun Zhao; Xue-Feng Li; Ran Xu
Journal:  PLoS One       Date:  2016-07-01       Impact factor: 3.240

10.  Droplet Digital PCR Based Androgen Receptor Variant 7 (AR-V7) Detection from Prostate Cancer Patient Blood Biopsies.

Authors:  Yafeng Ma; Alison Luk; Francis P Young; David Lynch; Wei Chua; Bavanthi Balakrishnar; Paul de Souza; Therese M Becker
Journal:  Int J Mol Sci       Date:  2016-08-04       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.